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Abstract 
FXR1 (Fragile X mental retardation-related protein 1) is a cytoplasmic RNA binding protein (Siomi et al., 
1995), which genetic expression has been related to metastatic potential in human melanoma. The 
aims of the present study were to validate two commercially available clones of polyclonal anti-human 
FXR1 antibody in dogs and to use them to investigate FXR1 expression in a group of canine oral 
melanomas. Anti-FXR1 antibody was never validated before in the canine species. 
Two different commercially available polyclonal anti-FXR1 antibodies (raised in goat and rabbit, 
respectively) were used. FXR1 protein in canine serum was identified by western blot after SDS-PAGE, 
using human serum as control. FXR1 immunohistochemical expression was tested in a series of normal 
tissues, that are expected to express FXR1, and in 31 cases of oral melanomas. The final 
immunohistochemical protocol used heat-induced unmasking and overnight incubation. 
FXR1 protein bands in canine serum were detected by validated antibodies. The rabbit antibody 
specifically identified a band around 65 kDa (Figure 1A), whereas the goat antibody reacted also with 
other not specific bands. FXR1 immunohistochemical staining was positive in all tested organs, with 
different levels of expression. FXR1 was also expressed in 31/31 tested melanomas, with variable 
intensity and percentage of positive cells (Figure 1B). Equal results were achieved with the two 
antibodies in 8 cases of melanoma, whereas there were variable differences in 22, and one case 
stained only with goat antibody. The rabbit antibody gave less background staining. This study 
validated anti-FXR1 antibodies for use in the canine species. This protein was identified in several 
normal tissues, as well as in the tested neoplasms. Significance of different level of expression is 
undergoing evaluation with further studies. 
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Figure 1. A) Western blot, rabbit anti-FXR1 antibody, positive bands around 65 kDa. B) Immunohistochemistry, oral 
melanoma, cytoplasmic positivity of neoplastic cells to FXR1. Rabbit anti-FXR1 antibody, AEC chromogen, 40x. 
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